RELAPSING MULTIPLE SCLEROSIS

This study tests whether a new drug, fenebrutinib, is better than an existing medication (teriflunomide) at reducing relapses and slowing disability in people with relapsing multiple sclerosis. About 746 adults with MS will be randomly assigned to one of the two treatments. The m…

This study follows 106 people with relapsing multiple sclerosis in Austria to see if starting the drug Ofatumumab (Kesimpta) earlier makes a difference compared to starting it later. Over two years, researchers track how well the drug controls disease activity, including relapses…

This study compares a new medication, remibrutinib, to an existing drug, teriflunomide, in about 1,000 adults with relapsing multiple sclerosis. The goal is to see which one better reduces the number of relapses and slows disability. Participants will be followed for several year…

This study compares a new drug, fenebrutinib, with an approved medication (teriflunomide) in about 750 adults with relapsing multiple sclerosis. The goal is to see if fenebrutinib better reduces relapse rates and delays disability progression. Participants take one of the two pil…

This study follows about 1,800 people with relapsing multiple sclerosis who have already taken ofatumumab in a previous Novartis trial. Researchers want to see how safe and effective the drug is over the long term, including its effects on vaccines and COVID-19 immunity. Particip…

This study tests whether fenebrutinib can reduce brain lesions in people with relapsing multiple sclerosis (RMS). About 109 participants received either the drug or a placebo, and brain scans were taken over 12 weeks. The goal is to see if fenebrutinib slows disease activity, wit…

This study looks at the long-term safety of the drug tolebrutinib in adults with multiple sclerosis (MS). It includes 2,500 people who have already taken part in earlier trials of this drug. Researchers will track side effects and check if the drug continues to help control the d…

This study tests a new oral drug, remibrutinib, against an approved drug, teriflunomide, in about 1000 adults with relapsing multiple sclerosis. The goal is to see if remibrutinib better reduces relapse rates and slows disability. Participants will first receive either drug in a …

This study tests an experimental drug called obexelimab in 93 people with relapsing multiple sclerosis (MS). The goal is to see if it can reduce new brain lesions and relapses better than a placebo. Participants receive either the drug or a placebo, and their brain scans and symp…

This study is testing whether the drug Ocrevus can improve walking, balance, and leg strength in people with relapsing multiple sclerosis (MS) compared to other standard MS medications. Sixty participants will be assigned to receive either Ocrevus or another treatment for one yea…

This study looks at how ocrelizumab, a multiple sclerosis (MS) drug, changes certain markers in the spinal fluid of people newly diagnosed with relapsing MS or a high-risk first episode. Researchers want to see if early treatment can reduce signs of chronic inflammation in the br…